Skip to main content

Non-Radiographic Axial Spondyloarthritis News

UCB announces U.S. FDA approvals for Bimzelx (bimekizumab-bkzx) for the treatment of psoriatic arthritis, non-radiographic axial spondyloarthritis and ankylosing spondylitis

Brussels (Belgium), September 23, 2024 – 07:00 (CEST) – UCB, a global biopharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has approved Bimzelx (bi...

FDA Approves Novartis Cosentyx as First Intravenous (IV) Formulation Interleukin-17A Antagonist for Rheumatic Diseases

EAST HANOVER, N.J., Oct. 6, 2023 /PRNewswire/ – Novartis, a global leader in immuno-dermatology and rheumatology, announced today that the US Food and Drug Administration (FDA) has approved an...

Rinvoq (upadacitinib) Receives FDA Approval for the Treatment of Adults with Active Non-Radiographic Axial Spondyloarthritis

Rinvoq is now approved as the first and only oral JAK inhibitor for adults with active non-radiographic axial spondyloarthritis (nr-axSpA) Rinvoq is the first and only JAK inhibitor approved for...

Ask a question

To post your own question to our community, sign in or create an account.

Further information

Related condition support groups

Spondyloarthritis

Related drug support groups

Cosentyx, Cimzia, Taltz